This company has been marked as potentially delisted and may not be actively trading. Novus Therapeutics (NVUS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock NVUS vs. IBIO, AEON, OBSV, AEZS, NRBO, ORGS, CPHI, MTNB, SPRB, and NBYShould you be buying Novus Therapeutics stock or one of its competitors? The main competitors of Novus Therapeutics include iBio (IBIO), AEON Biopharma (AEON), ObsEva (OBSV), Aeterna Zentaris (AEZS), NeuroBo Pharmaceuticals (NRBO), Orgenesis (ORGS), China Pharma (CPHI), Matinas Biopharma (MTNB), Spruce Biosciences (SPRB), and NovaBay Pharmaceuticals (NBY). These companies are all part of the "medical" sector. Novus Therapeutics vs. Its Competitors iBio AEON Biopharma ObsEva Aeterna Zentaris NeuroBo Pharmaceuticals Orgenesis China Pharma Matinas Biopharma Spruce Biosciences NovaBay Pharmaceuticals Novus Therapeutics (NASDAQ:NVUS) and iBio (NYSE:IBIO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends. Which has preferable valuation and earnings, NVUS or IBIO? Novus Therapeutics has higher earnings, but lower revenue than iBio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovus TherapeuticsN/AN/A-$16.01M-$21.58-0.17iBio$375K32.29-$24.91MN/AN/A Is NVUS or IBIO more profitable? iBio's return on equity of -73.15% beat Novus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Novus TherapeuticsN/A -133.49% -30.52% iBio N/A -73.15%-45.51% Do insiders and institutionals hold more shares of NVUS or IBIO? 7.9% of iBio shares are held by institutional investors. 2.2% of Novus Therapeutics shares are held by insiders. Comparatively, 0.6% of iBio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts recommend NVUS or IBIO? iBio has a consensus price target of $5.00, suggesting a potential upside of 582.04%. Given iBio's stronger consensus rating and higher possible upside, analysts clearly believe iBio is more favorable than Novus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00iBio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, NVUS or IBIO? Novus Therapeutics has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500. Comparatively, iBio has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Does the media prefer NVUS or IBIO? In the previous week, Novus Therapeutics' average media sentiment score of 0.00 equaled iBio'saverage media sentiment score. Company Overall Sentiment Novus Therapeutics Neutral iBio Neutral SummaryiBio beats Novus Therapeutics on 6 of the 10 factors compared between the two stocks. Get Novus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NVUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NVUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVUS vs. The Competition Export to ExcelMetricNovus TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.20M$776.92M$5.69B$9.50BDividend YieldN/A4.84%4.58%4.01%P/E Ratio-0.161.4028.1020.05Price / SalesN/A25.35432.4490.07Price / CashN/A19.5636.2258.56Price / Book0.286.798.665.87Net Income-$16.01M-$4.32M$3.25B$258.55M Novus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVUSNovus TherapeuticsN/A$3.62-2.9%N/A+24.3%$5.20MN/A-0.167Gap UpHigh Trading VolumeIBIOiBio1.2611 of 5 stars$0.72-5.2%$4.30+493.2%-66.9%$11.98M$375K0.00100AEONAEON Biopharma2.5904 of 5 stars$0.80-4.3%$360.00+44,956.3%-99.6%$9.03MN/A4.445OBSVObsEvaN/AN/AN/AN/A$7.94MN/A-0.1150AEZSAeterna ZentarisN/A$3.62+2.5%N/A-28.5%$6.49M$2.37M-0.2420Gap DownNRBONeuroBo PharmaceuticalsN/A$0.71-1.1%N/A-82.0%$6.12MN/A0.0010High Trading VolumeORGSOrgenesis1.7355 of 5 stars$1.19+0.8%N/AN/A$5.71M$662K0.00150Gap UpCPHIChina Pharma0.4824 of 5 stars$1.70-10.1%N/A-92.4%$5.55M$4.30M0.00250Positive NewsGap DownHigh Trading VolumeMTNBMatinas BiopharmaN/A$0.99-1.0%N/AN/A$5.04MN/A-0.2030Gap DownSPRBSpruce Biosciences2.1235 of 5 stars$0.10-6.3%$1.75+1,711.6%-78.5%$4.08M$4.91M-0.1020News CoverageStock SplitGap DownNBYNovaBay Pharmaceuticals1.5773 of 5 stars$0.67-2.9%$0.85+26.9%-65.3%$3.90M$9.78M-0.0130 Related Companies and Tools Related Companies IBIO Alternatives AEON Alternatives OBSV Alternatives AEZS Alternatives NRBO Alternatives ORGS Alternatives CPHI Alternatives MTNB Alternatives SPRB Alternatives NBY Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NVUS) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
